— Know what they know.
Not Investment Advice

VYNE NASDAQ

VYNE Therapeutics Inc.
1W: -28.6% 1M: +4282.4% 3M: +4327.2% YTD: +4825.0% 1Y: +2031.3% 3Y: +556.5% 5Y: -42.3%
$28.56
Last traded 2026-07-27 — delisted
NASDAQ · Healthcare · Biotechnology · $19.1M mcap · 613692 float · 4.11% daily turnover · Short 31% of daily vol

Cash Flow Trends

Operating Cash Flow
-$33M +2.5% ▲
Capital Expenditures
$0 +100.0% ▲
Free Cash Flow
-$33M +2.8% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +100.0% ▲
Net Change in Cash
$4M +138.2% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$73M-$23M-$28M-$40M-$26M
Depreciation & Amort.$109K$72K$0$4K-$755K
Stock-Based Comp.$8M$4M$3M$3M$2M
Change in Working Capital$5M$2M$60K$5M-$8M
Other Non-Cash Items$2M-$13M-$254K-$2M$0
Operating Cash Flow-$56M-$29M-$25M-$34M-$33M
— Investing Activities —
Capital Expenditures$0$0$0-$117K$0
Acquisitions (Net)$0$16M$5M$0$0
Investment Purchases$0$0-$62M-$61M-$31M
Investment Sales$1M$0$0$84M$68M
Other Investing$0$0$0$0$0
Investing Cash Flow$1M$16M-$57M$23M$37M
— Financing Activities —
Net Debt Issuance-$36M$0$0$0$0
Stock Repurchased$0$0$0-$141K$0
Dividends Paid$0$0$0$0$0
Other Financing$228K-$28K-$67K$0-$143K
Financing Cash Flow$40M$2M$82M-$141K-$143K
Net Change in Cash-$16M-$12M-$301K-$11M$4M
Cash End of Period$43M$31M$31M$20M$24M
Free Cash Flow-$56M-$29M-$25M-$34M-$33M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms